Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy - are these Receptors Valid Therapeutic Targets

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|10|1|42-50

ISSN： 1389-4501

Source： Current Drug Targets, Vol.10, Iss.1, 2009-01, pp. : 42-50

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy

By  

Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol. 12, Iss. 3, 2013-06 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced glycation end products and diabetic complications

By Stitt Alan W   Jenkins Alicia J   Cooper Mark E  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 9, 2002-09 ,pp. : 1205-1223

Informa Healthcare

Access to resources Recommend Favorite

Role of Advanced Glycation End Products in Diabetic Neuropathy

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 953-961

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products and Diabetic Retinopathy

By  

Current Medicinal Chemistry, Vol. 20, Iss. 26, 2013-09 ,pp. : 3234-3240

Bentham Science Publishers

Access to resources Recommend Favorite

The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.

By  

Current Clinical Pharmacology, Vol. 8, Iss. 4, 2013-11 ,pp. : 285-296

Bentham Science Publishers

Access to resources Recommend Favorite